These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 18484778)

  • 21. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
    Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
    Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical techniques for the evaluation of liquid protein therapeutics.
    Tatford OC; Gomme PT; Bertolini J
    Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):67-81. PubMed ID: 15270709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical development and characterization of an intravenous dosage form for the ACE inhibitor RS-10029.
    Visor GC; Lin LH; Henry P; Singer L
    J Parenter Sci Technol; 1989; 43(6):271-6. PubMed ID: 2600732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of primary packaging on the quality of parenteral products.
    Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B
    J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes.
    Sharma B
    Biotechnol Adv; 2007; 25(3):325-31. PubMed ID: 17337334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Current perspectives on the repackaging and stability of solid oral doses].
    Lagrange F
    Ann Pharm Fr; 2010 Nov; 68(6):332-58. PubMed ID: 21073993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Lyophilization Key for Transportation and Storage of Biopharmaceutical Drug Products in Space?
    Menzen T
    J Pharm Sci; 2024 Jul; 113(7):1695-1700. PubMed ID: 38701895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stress Factors in Protein Drug Product Manufacturing and Their Impact on Product Quality.
    Das TK; Sreedhara A; Colandene JD; Chou DK; Filipe V; Grapentin C; Searles J; Christian TR; Narhi LO; Jiskoot W
    J Pharm Sci; 2022 Apr; 111(4):868-886. PubMed ID: 34563537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Part II: Matrix based scaffold lyophilization facilitates processing as a prerequisite for an innovative packaging system.
    Kullmann D; Lema Martinez C; Lümkemann J; Huwyler J
    Eur J Pharm Biopharm; 2023 Mar; 184():262-273. PubMed ID: 36565968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility, stability and release performance of a time-dependent insulin delivery system intended for oral colon release.
    Maroni A; Del Curto MD; Serratoni M; Zema L; Foppoli A; Gazzaniga A; Sangalli ME
    Eur J Pharm Biopharm; 2009 May; 72(1):246-51. PubMed ID: 19121388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of formulation in insulin comparability assessments.
    Defelippis MR; Larimore FS
    Biologicals; 2006 Mar; 34(1):49-54. PubMed ID: 16330222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations for Implementation of a New Drug Substance Container for Subzero Storage.
    Rayfield WJ; McKechnie WS; Kandula S
    J Pharm Sci; 2021 Mar; 110(3):1067-1076. PubMed ID: 33359313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chitosan nanoparticles for drug delivery to the eye.
    Paolicelli P; de la Fuente M; Sánchez A; Seijo B; Alonso MJ
    Expert Opin Drug Deliv; 2009 Mar; 6(3):239-53. PubMed ID: 19290841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical stability and resistance to peroxidation of a range of liquid-fill hard gelatin capsule products on extreme long-term storage.
    Bowtle W; Kanyowa L; Mackenzie M; Higgins P
    Drug Dev Ind Pharm; 2011 Jun; 37(6):685-93. PubMed ID: 21449698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential clinical impact of compounded versus noncompounded intrathecal baclofen.
    Moberg-Wolff E
    Arch Phys Med Rehabil; 2009 Nov; 90(11):1815-20. PubMed ID: 19887203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postproduction Handling and Administration of Protein Pharmaceuticals and Potential Instability Issues.
    Nejadnik MR; Randolph TW; Volkin DB; Schöneich C; Carpenter JF; Crommelin DJA; Jiskoot W
    J Pharm Sci; 2018 Aug; 107(8):2013-2019. PubMed ID: 29665382
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality by design - Spray drying of insulin intended for inhalation.
    Maltesen MJ; Bjerregaard S; Hovgaard L; Havelund S; van de Weert M
    Eur J Pharm Biopharm; 2008 Nov; 70(3):828-38. PubMed ID: 18755270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploring the use of novel drug delivery systems for antiretroviral drugs.
    Ojewole E; Mackraj I; Naidoo P; Govender T
    Eur J Pharm Biopharm; 2008 Nov; 70(3):697-710. PubMed ID: 18655830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.